Compare AMCX & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMCX | BWAY |
|---|---|---|
| Founded | 1980 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Medical/Dental Instruments |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 339.5M | 337.9M |
| IPO Year | 2011 | 2019 |
| Metric | AMCX | BWAY |
|---|---|---|
| Price | $9.62 | $17.10 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $6.50 | ★ $23.50 |
| AVG Volume (30 Days) | ★ 408.8K | 62.4K |
| Earning Date | 11-07-2025 | 11-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 213.09 |
| EPS | N/A | ★ 0.13 |
| Revenue | ★ $2,316,303,000.00 | $49,094,000.00 |
| Revenue This Year | N/A | $330.76 |
| Revenue Next Year | N/A | $22.24 |
| P/E Ratio | ★ N/A | $51.80 |
| Revenue Growth | N/A | ★ 27.08 |
| 52 Week Low | $5.41 | $7.84 |
| 52 Week High | $10.60 | $18.18 |
| Indicator | AMCX | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 63.72 | 54.19 |
| Support Level | $9.59 | $15.97 |
| Resistance Level | $9.91 | $17.38 |
| Average True Range (ATR) | 0.37 | 0.68 |
| MACD | -0.02 | -0.10 |
| Stochastic Oscillator | 61.85 | 51.25 |
AMC Networks owns several linear pay-TV networks, including AMC, WE tv, BBC America, IFC, and SundanceTV. AMC, its most widely distributed network, reached 60 million pay-TV households in the US at the end of 2024. The firm also had nearly 12.5 million US streaming subscribers, with AMC+ as the flagship streaming platform. With both its linear networks and streaming offerings, the firm caters to specific niche audiences. Over the last 15 years, AMC has shifted its focus to original scripted programming from classic movies. It creates content through AMC Studios and also generates revenue from licensing content. Following an international divestiture at the end of 2023, domestic operations make up nearly 90% of total revenue.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.